Levetiracetam Neuraxpharm granules for oral solution in sachet
Published: 1 October 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification. Neuraxpharm UK Limited has informed the MHRA that a review of the approved Patient Information Leaflet (PIL) has identified discrepancies between the current Neuraxpharm product safety information and the corresponding reference product information.
Currently all available stock is impacted. These products have been considered critical for patients who are unable to take tablet formulations and rely on this dosage form. Therefore, the affected batches will continue to be supplied without repackaging.
Further information, advice and details of the affected batches can be found on the MHRA website.